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The following is a case report of a primiparous woman who developed fulminant liver failure in the setting of HELLP syndrome
complicated by hepatic rupture. It is unique in that a timely ABO compatible liver donor was unavailable, necessitating the
transplantationofanABOincompatibleorgan.Despiteaggressivetherapy,severereperfusioninjury andhumoralrejectiondictated
retransplantation with an ABO compatible organ on postoperative day 15, resulting in rapid clinical recovery.
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1.Introduction
Hemolysis, elevated liver enzymes, and low platelet count
(HELLP) syndrome is an uncommon, but potentially life
threateningcauseofacuteliverfailureinperipartumwomen.
Itoccursin0.2–0.6%ofallpregnancies,butcanbepresentin
up to 4–12% of cases with severe pre-eclampsia [1]. In about
30%ofcases,thediseasepresentspostpartum,usuallywithin
48 hours of delivery [2]. HELLP syndrome is associated
with a mortality of 1.1% and management typically involves
urgentdelivery andaggressivesupportive care.Themortality
associated with this condition is dramatically worsened
when there is hepatic rupture [3, 4]. The following is a
report of such a case initially treated with ABO incompatible
liver transplantation and ultimately with ABO compatible
transplantation.
2.CaseReport
A 28-year-old Gravida 1 Caucasian female without signif-
icant medical history presented to her obstetrician for a
routine oﬃce visit at 37 weeks gestation. Her examination
revealed a blood pressure of 150/98mmHg, 1+ pedal edema,
and 1+ proteinuria. Further laboratories demonstrated a
hemoglobin of 10.1g/dL, platelet count 106K/mm3, aspar-
tate aminotransferase (AST) 290IU/L, and lactate dehydro-
genase (LDH) of 371IU/L. She was presumptively diagnosed
with HELLP syndrome and admitted for urgent Caesarean
section.
While the surgery was uneventful, several hours later she
developed acute lower back pain and hypotension. Repeat
laboratory studies showed hemoglobin of 6.0g/dL, platelet
count 10K/mm3, AST 1696IU/L, alanine aminotransferase
(ALT) 1253IU/L, LDH 1262IU/L. Abdominal ultrasound
and CT demonstrated subcapsular and perihepatic hemor-
rhagewithfreeintraabdominalblood.Shewastransfusedred
blood cells and platelets and treated with high doses of intra-
venous corticosteroids. Vasopressor agents were required
to maintain adequate blood pressure and continuous renal
replacement therapy (CRRT) was instituted for anuric renal
failure.
Four days after delivery, her mental status deteriorated.
She was endotracheally intubated and transferred to our
institutionforfurthermanagement.Uponarrival,laboratory
studies showed hemoglobin 8.4g/ dL, platelets 39K/mm3,
international normalized ratio 1.49, factor V 32%, blood
type O, AST 1319IU/L, ALT 763IU/L, bilirubin 7.6mg/dL,
LDH 2215IU/L, creatinine 4.1mg/dL, and lactic acid2 Gastroenterology Research and Practice
Figure 1: Native liver: 3000g liver (expected weight 1500–1800g)
with dull yellow-green geographic necrosis and subcapsular blood.
5.1mmol/L. Serologic evaluation for other causes of liver
disease and human immunodeﬁciency virus was negative.
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evidence of abdominal compartment syndrome. Head CT
showed no apparent cerebral edema.
As there were no signs of improvement despite intensive
therapy for fulminant hepatic failure, six days postpartum
she was listed for liver transplantation as a United Network
of Organ Sharing (UNOS) status 1. Over the next ﬁve days,
her clinical course deteriorated further, necessitating 100%
forced inspiratory oxygen and high dose vasopressors. Since
no suitable ABO compatible livers had been oﬀered, on the
ﬁfth day after listing (11 days postpartum), the decision was
made to accept a blood type A1 liver.
Orthotopic liver transplantation was performed using
the piggyback technique. The donor was 31 years old with
a body mass index of 24kg/m2. No gross fatty change was
appreciated; liver biopsy was not performed. Cold ischemic
time was six hours and 40 minutes and warm ischemic
time was 23 minutes. Gross inspection of the native liver
revealedobvioushepaticrupture,withtheorgansurrounded
by hematoma (Figure 1). Histology demonstrated massive
hepatic necrosis, marked steatosis, widespread bile ductular
proliferation, profound cholestasis, and necrotic vessels with
intravascular thrombi (Figures 2 and 3).
She was treated with a renal-sparing immunosuppressive
regimen including high dose intravenous immune glob-
ulin, thymoglobulin, methylprednisolone, mycophenolate
Mofetil, and, beginning on day 7, tacrolimus. Daily plasma
exchangewasperformedwithbloodgroupAantigenspeciﬁc
immunoadsorbent columns. Over the ﬁrst seven days, serum
transaminases and coagulation studies steadily improved,
although she continued to require full ventilatory support
and CRRT. Although somnolent, she became arousable to
stimulation. Over the next 48 hours, however, the transam-
inases and bilirubin worsened. Liver biopsy demonstrated
mild reperfusion injury, mild cholangitis, spotty apoptosis,
but no cytopathic eﬀect or endothelialitis. A C4d stain
was negative. Direct antiglobulin and Coomb’s tests were
negative on three separate occasions. Biliary obstruction, vas-
cular thromboses and infections, including cytomegalovirus,
Figure 2: Native liver (40x, H&E section): at low power, one may
appreciate the interface between viable and necrotic hepatic tissue.
Figure 3: Native liver (100x, H&E section): higher power view of
the interface in the native liver between viable and necrotic hepatic
tissue. Note the cytologic changes of hepatocellular injury in the
viable tissue.
were excluded (Figure 4). On postoperative day 11, she
was comatose and laboratory studies showed bilirubin
14.5mg/dL, AST 1747IU/L, ALT 939IU/L, INR 1.75. As
a result of continued deterioration, she was relisted for
transplantation with a MELD score of 35 on postoperative
day 15.
An ABO compatible liver became available within 24
hours. Histology of the failed allograft demonstrated numer-
ous areas of hemorrhagic necrosis; 30% of the left lobe was
completely necrotic (Figures 5, 6,a n d7). On post-operative
day 1, the patient became alert and oriented. Over the next
severalweeksshewasextubatedandCRRTwasdiscontinued.
She was discharged on post-operative day 32 (17 days after
re-transplantation) with baseline mental status and normal
serum liver tests and creatinine. She and her baby are alive
and well thirty months after transplant.
3. Discussion
Hepatic rupture is an unusual, but potentially grave,
complication of HELLP syndrome. Emergency laparotomyGastroenterology Research and Practice 3
Figure 4: First allograft (400x, H&E section): portal areas show
areas of cholangitis. No features of acute cellular rejection. The
parenchyma surrrounding this portal area appears viable.
Figure 5: Explant of Allograft: 2531g liver (expected weight 1500-
1800g) congested parenchyma with approximately 30% necrosis of
the left lobe.
is required for acute compartment syndrome or ongoing
bleeding. Interventions at the time of surgery can include
temporary packing of the liver, evacuation of a hematoma,
suturing of a laceration, ligation of the hepatic artery, and/or
resection of necrotic liver [5, 6].
Liver transplantation is rarely required for HELLP
syndrome, but is more likely to be necessary if there is
hepatic rupture [7]. Transplantation may be necessary for
unrelenting bleeding or fulminant liver failure. Shames et al.
detailed such a case and found only 7 other patients in the
UNOSdatabasefrom1987–2004inwhomHELLPsyndrome
wastheindicationforlivertransplantation.Sixoftheseseven
patients survived and two required re-transplantation, both
for infectious issues [5].
Our case report is unique in that an ABO incompat-
ible liver (A1→O) unintentionally served as a “bridge” to
successful transplantation with an ABO compatible organ to
treat fulminant hepatic failure secondary to HELLP syndrome.
Once the decision was made to list our patient as a UNOS
status 1, no suitable blood type O liver was available for
ﬁve days, two days longer than the median wait time in our
region. Given the rapidly declining clinical status of a young
Figure 6: Allograft (40x, H&E section).
and otherwise healthy new mother, it was determined that
the potential beneﬁt of crossing the ABO barrier outweighed
the medical and ethical risks. We proceeded with ABO
incompatible transplantation with full expectations of patient
and graft survival. Only when the ABO incompatible graft
failed from a combination of reperfusion injury and humoral
rejection, did we resort to relisting the patient for an ABO
compatible organ.
ABO incompatible liver transplantation is infrequently
utilized since the high risks of antibody mediated rejection,
vascular thrombosis, and ischemic bile duct complications
are associated with reduced patient and graft survival [8–
11]. Transplanting A1 (rather than A2) →O presents greater
challenges as enhanced expression of A antigen may intensify
isohemagglutinin mediated rejection.
Several strategies have been employed to try to minimize
humoral rejection in ABO incompatible liver transplanta-
tions. Pre-and posthigh volume plasma exchange or blood
group speciﬁc immunoadsorbent columns may be utilized
to reduce preformed complement-ﬁxing antibodies [12–14].
Some centers follow hemagglutinin titers to monitor such
therapy, particularly during the high risk period of the ﬁrst
few postoperative weeks [12, 13]. While older aggressive
immunosuppressive regimens complemented cyclophos-
phamide and OKT3 treatment with splenectomy [12], more
recently, mycophenolate mofetil, daclizumab induction,
and/or anti-CD20 monoclonal antibody have been used
successfully in small case series [14]. In Japan, where up
to 5% of adult living donor liver transplantation involve
ABO incompatible organs, supplemental postoperative por-
tal vein infusions with methylprednisolone, prostaglandin
E1, and/or gabexate mesylate have been used to control local
disseminated intravascular coagulation [15].
In our case, aggressive immunosuppression, intravenous
immune globulin, and immunoadsorption with immobilized
A antigen was associated with fair early graft function. The
clinical deterioration which occurred after approximately
one week, combined with the biopsy ﬁndings of hepatic
necrosis, cholangitis, and apoptosis was consistent with
refractory antibody-mediated rejection. Deﬁnitively diag-
nosing humoral rejection as the sole cause of graft failure4 Gastroenterology Research and Practice
Figure7:Allograft(100x,H&Esection):higherpowerviewoflarge
zones of necrosis abutting adjacent viable hepatic tissue.
may be challenging. Biopsy ﬁndings are typically not path
gnomonic, although periportal edema and necrosis may
be early ﬁndings [16]. Other coexisting pathology, such
as preservation injury and acute cellular rejection, may
occur simultaneously and confound biopsy interpretation
[17]. Sinusoidal deposition of hemagglutinins and their
complements may be seen by immunohistochemical analysis
in humoral rejection [16]. While not conﬁrmatory in our
case, positive C4d (a degraded product of complement C4)
immunostaining has been associated in some instances with
high antidonor antibody titers and relatively poorer overall
survival rate [17]. With our patient, one could speculate
whether further intensifying the immunosuppression or
performing splenectomy would have stabilized the clinical
course or merely increased the likelihood of sepsis and
multiorgan failure. The rapid clinical improvement once an
ABO compatible liver was transplanted further supports the
hypothesis that antibody mediated rejection contributed to
failure of the ﬁrst graft.
Patients with HELLP syndrome complicated by hepatic
rupture should be transferred to a liver transplantation cen-
ter for management and emergent evaluation for liver trans-
plantation. While ABO incompatible transplantation should
be considered in only exceptional circumstances, antigen-
speciﬁcimmunoadsorption,aggressiveimmunosuppression,
consideration of portal vein infusion therapy, and even
splenectomy may optimize outcomes in this setting. Even
utilizing these extraordinary measures, graft and patient
survival still remains inferior to results with ABO compatible
livers.
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